|
Mar 31
|
Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street
|
|
Mar 31
|
Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'
|
|
Mar 31
|
Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out
|
|
Mar 29
|
Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy?
|
|
Mar 28
|
Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?
|
|
Feb 20
|
Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now?
|
|
Feb 17
|
Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround
|
|
Feb 14
|
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
|
|
Feb 12
|
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
|
|
Feb 11
|
Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call
|
|
Jan 20
|
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
|
|
Dec 20
|
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam
|
|
Dec 19
|
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
|
|
Dec 19
|
Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trial
|
|
Dec 19
|
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
|
|
Dec 18
|
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
|
|
Dec 18
|
Tessera gets sickle cell funding; Corvus shares slide on eczema data
|
|
Dec 17
|
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
|
|
Oct 16
|
Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Biotech Stock According to Hedge Funds?
|
|
Sep 8
|
Sarepta Therapeutics, Inc. (SRPT): This Biotech Stock Should Be On Your Radar
|